| CAS NO: | 1984890-99-4 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 1984890-99-4 |
| 分子式 | C47H54N6O3 |
| 分子量 | 750.97 |
| 溶解度 | DMSO : 100 mg/mL (133.16 mM; Need ultrasonic) |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | ACT-451840 is an orally active, potent and low-toxicity compound, showing activity against sensitive and resistant plasmodium falciparum strains. ACT-451840 targets all asexual blood stages of the parasite, has a rapid onset of action. ACT-451840 behaves in a way similar to artemisinin derivatives, with very rapid onset of action and elimination of parasite. ACT-451840 can be used for the research of malarial[1][2][3]. ACT-451840 shows a 50 % inhibition concentration of 0.4 nM against the drug-sensitive P. falciparum NF54 strain. The IC50 value of ACT-451840 against the murine malaria parasite P. berghei is 13.5 nM in in vitro ex vivo assays. ACT-451840 (10 and 60 mg kg) starts to show significant antimalarial effects (parasite reduction) in vivo at 20 mg/kg. ACT-451840 exhibits curative activity at 300 mg/kg and significant antimalarial effects already at 100 mg/kg. ACT-451840 shows excellent reduction at 30 mg/kg, resulting in 99.80 % activity[2]. ACT-451840 shows efficacy in the Plasmodium berghei mouse model[2]. [1]. Bruderer S, et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. Antimicrob Agents Chemother. 2015;59(2):935-942. |
m.cnreagent.com